7/14
07:58 am
anab
Laughing Water Capital Q2 2026 Letter [Seeking Alpha]
High
Report
Laughing Water Capital Q2 2026 Letter [Seeking Alpha]
6/10
08:04 am
anab
AnaptysBio (ANAB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $95.00 price target on the stock.
Low
Report
AnaptysBio (ANAB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $95.00 price target on the stock.
6/4
07:33 am
anab
AnaptysBio (ANAB) was downgraded by Zacks Research from "strong-buy" to "hold".
Low
Report
AnaptysBio (ANAB) was downgraded by Zacks Research from "strong-buy" to "hold".
5/21
10:57 pm
anab
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
Low
Report
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
5/15
01:00 pm
anab
AnaptysBio (ANAB) was given a new $90.00 price target by Leerink Partners.
Low
Report
AnaptysBio (ANAB) was given a new $90.00 price target by Leerink Partners.
5/14
06:00 pm
anab
AnaptysBio (ANAB) was downgraded by
Weiss Ratings from "sell (d-)" to "sell (e+)".
Medium
Report
AnaptysBio (ANAB) was downgraded by
Weiss Ratings from "sell (d-)" to "sell (e+)".
5/13
09:00 am
anab
AnaptysBio (ANAB) had its "buy" rating reaffirmed by UBS Group AG.
Medium
Report
AnaptysBio (ANAB) had its "buy" rating reaffirmed by UBS Group AG.
5/13
06:00 am
anab
AnaptysBio (ANAB) had its "overweight" rating reaffirmed by Barclays PLC.
Medium
Report
AnaptysBio (ANAB) had its "overweight" rating reaffirmed by Barclays PLC.
5/12
04:15 pm
anab
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
Low
Report
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
5/11
09:30 am
anab
AnaptysBio appoints Christopher Murphy as CFO [Seeking Alpha]
Low
Report
AnaptysBio appoints Christopher Murphy as CFO [Seeking Alpha]
5/11
09:15 am
anab
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
Low
Report
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
5/10
09:26 pm
anab
Assessing AnaptysBio (ANAB) Valuation After Royalty Pivot Spinoff And Legal Outcome [Yahoo! Finance]
Low
Report
Assessing AnaptysBio (ANAB) Valuation After Royalty Pivot Spinoff And Legal Outcome [Yahoo! Finance]
5/10
07:33 pm
anab
Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026? [Yahoo! Finance]
Low
Report
Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026? [Yahoo! Finance]
5/6
06:03 am
anab
AnaptysBio (ANAB) was upgraded by Zacks Research from "hold" to "strong-buy".
Medium
Report
AnaptysBio (ANAB) was upgraded by Zacks Research from "hold" to "strong-buy".
5/4
04:15 pm
anab
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
Low
Report
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
5/3
10:45 pm
anab
AnaptysBio (ANAB) Is Up 13.4% After Court Upholds Jemperli Royalty Rights In Tesaro Dispute [Yahoo! Finance]
Medium
Report
AnaptysBio (ANAB) Is Up 13.4% After Court Upholds Jemperli Royalty Rights In Tesaro Dispute [Yahoo! Finance]
4/28
09:00 am
anab
AnaptysBio (ANAB) was given a new $85.00 price target by Leerink Partners.
Low
Report
AnaptysBio (ANAB) was given a new $85.00 price target by Leerink Partners.
4/27
03:13 am
anab
GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio [Yahoo! Finance]
High
Report
GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio [Yahoo! Finance]
4/24
03:40 pm
anab
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim
High
Report
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim
4/22
09:24 am
anab
AnaptysBio (ANAB) had its price target lowered by Barclays PLC from $79.00 to $63.00. They now have an "overweight" rating on the stock.
Low
Report
AnaptysBio (ANAB) had its price target lowered by Barclays PLC from $79.00 to $63.00. They now have an "overweight" rating on the stock.
4/21
03:07 pm
anab
AnaptysBio: 'Hold' As Spin-Off Shifts Pipeline To First Tracks Biotherapeutics [Seeking Alpha]
Low
Report
AnaptysBio: 'Hold' As Spin-Off Shifts Pipeline To First Tracks Biotherapeutics [Seeking Alpha]
4/21
11:03 am
anab
AnaptysBio (ANAB) was given a new $60.00 price target by UBS Group AG.
Low
Report
AnaptysBio (ANAB) was given a new $60.00 price target by UBS Group AG.
4/20
09:15 am
anab
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
High
Report
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations